Latest Articles and Analysis

The Centers for Disease Control and Prevention (CDC) released its National HIV Prevention and Care Objectives: 2026 Update on May 18, 2026, presenting the most recent national picture of the U.S. HIV...

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

The HIV/HCV Co-Infection Watch is a project of the Community Access National Network (CANN) designed to research, monitor, and report on HIV and Hepatitis C (HCV) co-infection in the United States....

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Q1 2025 Watch: comprehensive update on HIV/HCV co-infection treatment access across federal and state programs.

CDC progress data on STI and overdose prevention initiatives shows mixed results.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

Opioid settlement funds risk misallocation; MAT gaps for minors and drug court issues identified.

DEA signals openness to telemedicine prescribing of controlled substances, expanding MAT access.

SAMHSA releases Harm Reduction Framework for federal substance use programming and community approaches.

Opioid settlement funds allocation overview: oversight and community impact considerations.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

DEA proposed rules restrict telemedicine prescribing, harming rural patients and transgender individuals.

Xylazine contamination of drug supply demands harm reduction response including safe consumption sites.

Nevada expands syringe vending machines with naloxone, fentanyl strips; anonymity critical for uptake.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.